In brief
The European Union's court emphasizes the necessity for public disclosure of crucial documents related to COVID-19 vaccine deals.
In a landmark decision on Wednesday, the European Union's General Court indicated a shift toward increased transparency regarding public interest matters, particularly surrounding the negotiations for COVID-19 vaccine access. The ruling arose from a case initiated by The New York Times against the European Commission in 2023, focusing on the commission’s refusal to release text messages exchanged between Ursula von der Leyen, the president of the European Commission, and Pfizer's CEO, Albert Bourla, during their 2021 negotiations for vaccine contracts.Central to the case was the legal determination of whether these text messages should be classified as public documents under European Union law and whether they ought to be retained and disclosed. The European Commission argued that the ephemeral nature of text messages rendered them exempt from the transparency requirements applicable to the bloc. However, the judges countered that the commission is obligated to provide reasonable explanations for why such documents are not available. In their ruling, they stated, “The commission cannot merely assert that it does not have the requested documents but must offer credible justification that enables the public and the court to ascertain why those documents are absent.” The judges further criticized the commission for inadequately justifying its belief that the text communications from the COVID-19 vaccine procurement negotiations lacked significant information.This ruling is poised to influence future cases related to public transparency in the European Union, emphasizing that even informal communications in critical negotiations must be subject to scrutiny and potentially disclosed to the public.
